男性乳腺癌内分泌治疗研究进展

文章信息/Info

• Title:男性乳腺癌内分泌治疗研究进展

• 卷期:2023年21卷24期

• 作者:周子椿 杨毅

• 山东中医药大学中医学院，山东济南，250014

• Author(s):Zhou Zichun Yang Yi

• School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine

• 关键词男性；乳腺癌；内分泌

• Keywords:male; breast cancer; endocrine

• 摘要:内分泌治疗是乳腺癌的重要治疗方式，对于大部分为激素受体阳性的男性乳腺癌来说，更是尤为重要。随着科技的发展，技术的进步，对于男性乳腺癌内分泌治疗的研究，虽然也不断深入，但大部分治疗方式仍是参照女性。目前他莫昔芬仍是男性乳腺癌内分泌治疗的首选,芳香化酶抑制剂联合促性腺激素释放激素、ER下调剂氟维司群以及CDK4/6抑制剂等靶向药物也慢慢投入临床应用。但对于男性乳腺癌内分泌治疗的研究仍需针对性、多方面的进行，以期改善患者生存及预后。                                                                                                                                                                                

• Abstract: Endocrine therapy is an important treatment for breast cancer, and it is especially important for most male breast cancers that are hormone receptor positive. With the development of science and technology, the advancement of technology, although the research on endocrine therapy for male breast cancer has also been deepened, most of the treatment methods are still based on women. At present, tamoxifen is still the first choice for endocrine therapy for male breast cancer, and targeted drugs such as aromatase inhibitors combined with gonadotropin-releasing hormones, ER downregulation agents fulvestrant and CDK4/6 inhibitors are also slowly being put into clinical application. However, research on endocrine therapy for male breast cancer still needs to be targeted and multifaceted in order to improve patient survival and prognosis.

  男性乳腺癌（male breast cancer,MBC）是临床上较为罕见的恶性肿瘤，其发病率约为乳腺癌的1%[1]。但近年来的调查研究显示，MBC发病率有增加趋势[2]。大部分MBC患者病理类型为激素受体阳性[3]。